TEVA-CLONIDINE TABLET

Country: Kanada

Bahasa: Inggeris

Sumber: Health Canada

Bahan aktif:

CLONIDINE HYDROCHLORIDE

Boleh didapati daripada:

TEVA CANADA LIMITED

Kod ATC:

C02AC01

INN (Nama Antarabangsa):

CLONIDINE

Dos:

0.2MG

Borang farmaseutikal:

TABLET

Komposisi:

CLONIDINE HYDROCHLORIDE 0.2MG

Laluan pentadbiran:

ORAL

Unit dalam pakej:

100/500

Jenis preskripsi:

Prescription

Kawasan terapeutik:

CENTRAL ALPHA-AGONISTS

Ringkasan produk:

Active ingredient group (AIG) number: 0108891002; AHFS:

Status kebenaran:

APPROVED

Tarikh kebenaran:

2013-12-13

Ciri produk

1
PRODUCT MONOGRAPH
PR
TEVA-CLONIDINE
(Clonidine Hydrochloride)
0.1 mg and 0.2 mg Tablets
USP
Antihypertensive
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Submission Control No: 171843
Date of Revision:
April 25, 2014
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY
PRODUCT
INFORMATION
................................................................................
3
INDICATIONS
AND
CLINICAL
USE
......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
3
WARNINGS
AND
PRECAUTIONS
.........................................................................................
4
ADVERSE
REACTIONS
...........................................................................................................
7
DRUG
INTERACTIONS
............................................................................................................
9
DOSAGE
AND
ADMINISTRATION
......................................................................................
11
OVERDOSAGE
........................................................................................................................
12
ACTION
AND
CLINICAL
PHARMACOLOGY
....................................................................
13
STORAGE
AND
STABILITY
.................................................................................................
14
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ..................................................... 14
PART II: SCIENTIFIC INFORMATION
...............................................................................
16
PHARMACEUTICAL
INFORMATION
.................................................................................
16
DETAILED
PHARMACOLOGY
............................................................................................
17
TOXICOLOGY
...........................